The effect of ephedrine plus caffeine on plasma lipids and lipoproteins during a 4.2 MJ/day diet
- PMID: 8061726
The effect of ephedrine plus caffeine on plasma lipids and lipoproteins during a 4.2 MJ/day diet
Abstract
The effect of treatment with a combination of ephedrine and caffeine during eight weeks' energy restriction (4.2 MJ/day) on the fasting plasma lipid profile was studied in obese women. Thirty-two women were randomly assigned to either ephedrine 20 mg plus caffeine 200 mg (EC) or placebo three times per day. Weight loss (7.8 +/- 0.63 kg) and loss of fat mass (6.2 +/- 0.49 kg) did not differ significantly between the two groups. Total cholesterol concentration declined from baseline to week 8 (0.58 +/- 0.13 mmol/l) with no significant difference between the two groups. HDL-cholesterol concentration was decreased by 0.14 +/- 0.03 mmol/l at week 4 and week 8 in the placebo group (P < 0.05) but remained unchanged in the EC group. No effect of dieting was seen on plasma triglyceride concentration in the placebo group but a decrease was observed in the EC group at week 8. It is suggested that EC combinations abolish the decline in HDL-cholesterol during active weight loss due to the beta-agonistic properties of ephedrine.
Similar articles
-
The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial.Int J Obes Relat Metab Disord. 1992 Apr;16(4):269-77. Int J Obes Relat Metab Disord. 1992. PMID: 1318281 Clinical Trial.
-
Safety and efficacy of long-term treatment with ephedrine, caffeine and an ephedrine/caffeine mixture.Int J Obes Relat Metab Disord. 1993 Feb;17 Suppl 1:S69-72. Int J Obes Relat Metab Disord. 1993. PMID: 8384186 Clinical Trial.
-
Comparison of an ephedrine/caffeine combination and dexfenfluramine in the treatment of obesity. A double-blind multi-centre trial in general practice.Int J Obes Relat Metab Disord. 1994 Feb;18(2):99-103. Int J Obes Relat Metab Disord. 1994. PMID: 8148931 Clinical Trial.
-
Pharmacology of thermogenic drugs.Am J Clin Nutr. 1992 Jan;55(1 Suppl):246S-248S. doi: 10.1093/ajcn/55.1.246s. Am J Clin Nutr. 1992. PMID: 1345887 Review.
-
Clinical aspects of ephedrine in the treatment of obesity.Int J Obes Relat Metab Disord. 1993 Feb;17 Suppl 1:S65-8. Int J Obes Relat Metab Disord. 1993. PMID: 8384185 Review. No abstract available.
Cited by
-
The Effect of an 8 Week Prescribed Exercise and Low-Carbohydrate Diet on Cardiorespiratory Fitness, Body Composition and Cardiometabolic Risk Factors in Obese Individuals: A Randomised Controlled Trial.Nutrients. 2020 Feb 14;12(2):482. doi: 10.3390/nu12020482. Nutrients. 2020. PMID: 32075010 Free PMC article. Clinical Trial.
-
Thermogenic drugs as a strategy for treatment of obesity.Endocrine. 2000 Oct;13(2):207-12. doi: 10.1385/ENDO:13:2:207. Endocrine. 2000. PMID: 11186222 Review.
-
Effects of Ephedrine-Containing Products on Weight Loss and Lipid Profiles: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Pharmaceuticals (Basel). 2021 Nov 22;14(11):1198. doi: 10.3390/ph14111198. Pharmaceuticals (Basel). 2021. PMID: 34832979 Free PMC article. Review.
-
Muscle uncoupling protein 3 expression is unchanged by chronic ephedrine/caffeine treatment: results of a double blind, randomised clinical trial in morbidly obese females.PLoS One. 2014 Jun 6;9(6):e98244. doi: 10.1371/journal.pone.0098244. eCollection 2014. PLoS One. 2014. PMID: 24905629 Free PMC article. Clinical Trial.
-
A Systematic Review of Dietary Supplements and Alternative Therapies for Weight Loss.Obesity (Silver Spring). 2021 Jul;29(7):1102-1113. doi: 10.1002/oby.23110. Obesity (Silver Spring). 2021. PMID: 34159755 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical